Labcyte Sciex Developing Peptide Quantitation Assays Using Acoustic Ejection System Premium The Echo MS, which can inject up to three samples per second into a mass spectrometer, could enable extremely high-throughput targeted peptide quantitation. Omics Tools Firms See Opportunities in Burgeoning Synthetic Biology Industry Premium Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors. ASMS 2019 Sees Slew of New Releases as Vendors Highlight Throughput, Ion Mobility Options Premium New instrument releases at this week's meeting reflected proteomics' increased emphasis on throughput and the continuing spread of ion mobility technology. AstraZeneca's Acoustic Mist Mass Spec Platform Can Run 100K Samples Daily Premium Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling. Beckman Coulter Life Sciences Acquires Labcyte Labcyte has developed an acoustic droplet ejection technology called Echo that uses sound energy for the contactless transfer of samples and reagents. Nov 8, 2017 Labcyte, U of Helsinki Extend Personalized Medicine Collaboration Dec 7, 2016 Notable Labs to Use Labcyte Technology in Cell-Based Individualized Cancer Therapy Selection Jun 12, 2015 Labcyte, U of Helsinki Extend Collaboration May 5, 2015 Labcyte Closes $17M Credit Facility Nov 22, 2013 LabCyte Wins $1M SBIR Grant to Continue Work with Stanford on MALDI-MS Protein Assays Premium Nov 20, 2013 NCI Awards Labcyte $1M to Develop Mass Spec-based Cancer Biomarker Detection Method Sep 25, 2013 Labcyte Collaborating with AstraZeneca on Acoustic Sample Handling for Mass Spec Analysis Jan 18, 2013 New Products: Phenomenex, LabCyte Premium Jan 9, 2013 Labcyte Closes $5.3M in Financing Jan 7, 2013 Finnish Institute to Use Labcyte Tech to Enhance Cancer Testing Studies Feb 9, 2012 Product Watch: Eppendorf, LabCyte, Sage Science, and Hamilton Robotics Premium Jan 30, 2012 Bruker, SISCAPA Assay Tech Study Suggests MALDI-MS Suitable for Clinical Protein Quantitation Premium Jan 26, 2012 New Products: Qiagen's FlexiPlate siRNA Libraries Premium Jan 24, 2012 Labcyte, Qiagen Team on siRNA Reagent Offering Jan 20, 2012 New Instruments, Applications Powering Rise of MALDI-MS as Clinical Proteomics Platform Premium Dec 8, 2011 Labcyte, Roche Integrate Liquid Handling, qPCR Tech for Compound Screening Applications Premium Dec 6, 2011 Roche, Labcyte Collaborate on qPCR-based Research Dec 2, 2011 SISCAPA-Based Biomarker Quantitation Moving to MALDI MS in Pursuit of Higher Throughput, Lower Costs Premium Nov 8, 2011 NCI Awards Labcyte $196K to Develop Cancer Biomarker Validation System Sep 8, 2011 Products & Services: Sep 8, 2011 Premium Load More Breaking News BostonGene, Johns Hopkins University Partner for Multiple Cancer Clinical Research Projects KromaTid, Noble Life Sciences Ink Distribution, OEM Agreement Promega to Develop Microsatellite Instability Companion Diagnostic Kit With GlaxoSmithKline ZeptoMetrix Quality Control Products Receive IVDR Certification Verily Awarded CDC Contract for Wastewater Surveillance The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.